Suven Life Sciences went up over 6.6% to Rs.284.05 and remains firmly in the green. Its 52-week high is at Rs.337.70 and low at Rs.163.30.
The company announced today morning that it has received one product patent from Canada and another one from Sri Lanka. These are for the New Chemical Entity for the treatment of disorders associated with Neurodegenerative diseases.
The Canadian patent is valid through 2034 and Sri Lankan one till 2026.
The granted claims of the patents are being developed as therapeutic agents for neurodegenerative disorders such as Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products.
Suven has 4 clinical stage compounds and 9 internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.